Omeros Stock (NASDAQ:OMER)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$3.83

52W Range

$2.95 - $13.60

50D Avg

$3.40

200D Avg

$6.62

Market Cap

$243.16M

Avg Vol (3M)

$1.21M

Beta

2.16

Div Yield

-

OMER Company Profile


Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

202

IPO Date

Oct 08, 2009

Website

OMER Performance


OMER Financial Summary


Dec 24Dec 23Dec 22
Revenue---
Operating Income$-169.26M$-164.53M$-163.39M
Net Income$-156.81M$-117.81M$28.78M
EBITDA$-169.26M$-163.61M$-162.44M
Basic EPS$-2.70$-1.88$0.46
Diluted EPS$-2.70$-1.88$0.46

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 25May 15, 25 | 4:30 PM
Q4 24Mar 31, 25 | 4:30 PM
Q3 24Nov 13, 24 | 4:30 PM

Peer Comparison


TickerCompany
OCULOcular Therapeutix, Inc.
OABIOmniAb, Inc.
FOLDAmicus Therapeutics, Inc.
PTCTPTC Therapeutics, Inc.
PLRXPliant Therapeutics, Inc.
CORTCorcept Therapeutics Incorporated
CABACabaletta Bio, Inc.
KPTIKaryopharm Therapeutics Inc.
TGTXTG Therapeutics, Inc.
PHATPhathom Pharmaceuticals, Inc.